Marc Meth, MD
Clinical & Laboratory Immunology · Los Angeles, CANPI 1508013301
Payments from drug & device makers
Across 535 payments — averaging $59.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron$11K
- Dermira, Inc.$5K
- Sanofi$2K
- Regeneron Healthcare Solutions, Inc.$2K
- Grifols USA, LLC$1K
- GSK$1K
- plus $8K from 31 others
What the payments were for
- Consulting fees$8,29939%
- Travel & lodging$1,0175%
- Food & beverage$11,77356%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron | 30 | $10,800 |
| Dermira, Inc. | 3 | $5,463 |
| Sanofi | 53 | $2,464 |
| Regeneron Healthcare Solutions, Inc. | 84 | $2,151 |
| Grifols USA, LLC | 6 | $1,488 |
| GSK | 37 | $1,148 |
| Optinose US, Inc. | 16 | $1,095 |
| AstraZeneca | 49 | $998 |
| Novartis | 27 | $887 |
| CSL Behring | 39 | $799 |
| Pfizer | 40 | $713 |
| AbbVie | 40 | $644 |
| Aerin Medical Inc. | 1 | $400 |
| Genentech USA, Inc. | 12 | $311 |
| Kaleo, Inc. | 12 | $289 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $265 |
| Amgen(2 entities) | 11 | $253 |
| Hikma Pharmaceuticals USA | 11 | $225 |
| Teva Pharmaceuticals USA, Inc. | 10 | $203 |
| Globus Medical | 1 | $160 |
| ARS Pharmaceuticals Operations, Inc. | 6 | $144 |
| Alk-abello, Inc | 6 | $141 |
| Boehringer Ingelheim | 6 | $127 |
| Bio Products Laboratory USA, Inc. | 4 | $113 |
| Sanofi-aventis U.S. LLC | 2 | $104 |
| Blueprint Medicines Corporation | 3 | $96 |
| Shire North American Group Inc | 2 | $67 |
| Octapharma USA, Inc. | 2 | $66 |
| Galderma Laboratories, L.p. | 2 | $48 |
| Incyte Corporation | 2 | $44 |
| Merck | 2 | $43 |
| Phadia US Inc. | 2 | $33 |
| Arcutis Biotherapeutics, Inc. | 1 | $23 |
| LEO Pharma Inc. | 1 | $23 |
| Pharming Healthcare, Inc. | 1 | $23 |
| Organon | 1 | $21 |
| Novo Nordisk | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few clinical & laboratory immunology providers in Californiato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 60 | $238,997 |
| NucalaMepolizumab | 26 | $111,313 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 29 | $20,418 |
| OzempicSemaglutide | 17 | $17,364 |
| Breo ElliptaFluticasone/Vilanterol | 28 | $9,766 |
| DuleraMometasone/Formoterol | 20 | $7,105 |
| SymbicortBudesonide/Formoterol Fumarate | 16 | $6,266 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 12 | $5,598 |
| OdactraMite,d.Farinae-D.Pteronyssinus | 16 | $5,513 |
| BreynaBudesonide/Formoterol Fumarate | 16 | $3,136 |
| Ipratropium Bromide | 83 | $2,024 |
| Levothyroxine Sodium | 41 | $1,532 |
| Mometasone Furoate | 12 | $1,137 |
| Atorvastatin Calcium | 94 | $1,112 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 12 | $780 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKNucala, Trelegy Ellipta, Breo Ellipta, Anoro Ellipta | $1,148 | $147,09695 claims |
| Novo NordiskOzempic | $17 | $17,36417 claims |
| MerckDulera | $43 | $7,10520 claims |
| AstraZenecaSymbicort | $998 | $6,26616 claims |
| Alk-abello, IncOdactra | $141 | $5,51316 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few clinical & laboratory immunology providers in Californiaon file to place this against a meaningful peer group, so we don't.
Other clinical & laboratory immunology in Los Angeles
- Jonathan CorrenLos Angeles$1.8M
- Rita KachruSanta Monica$106K
- Alexander Kimla Jolla$40K
- Joshua GibbsRancho Cucamonga$5K
- Sean LesonGarden Grove$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.